Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TORL-4-500 |
| Synonyms | |
| Therapy Description |
TORL-4-500 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to monomethyl auristatin E (MMAE), which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1896). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TORL-4-500 | TORL 4 500|TORL-4500|TORL4500 | TORL-4-500 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to monomethyl auristatin E (MMAE), which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1896). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06005740 | Phase I | TORL-4-500 | First in Human Study of TORL-4-500 in Participants With Advanced Cancer | Recruiting | USA | CAN | 0 |